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INTRODUCTION
Worldwide, 358 million people are estimated 
to be affected by asthma1 and 174 million 
by chronic obstructive pulmonary disease 
(COPD).2 Both diseases can vary greatly 
in their presentation, and imprecision 
of diagnosis in both diseases remains a 
problem.3,4 
Accurate diagnosis of asthma and COPD 
is essential as correct treatment of asthma 
and COPD can reduce the frequency and 
severity of exacerbations, and improve 
overall quality of life.2 In addition, information 
on chronic respiratory disease can help 
patients to quit smoking. 
The differential diagnosis of COPD and 
asthma rests on differences in clinical 
presentation, triggering factors, and on 
demonstration of airflow obstruction. This 
airflow obstruction is not fully reversible in 
COPD, whereas it is in asthma. However, 
differential diagnosis remains difficult; 
the existence of asthma–COPD overlap 
syndrome (ACOS) remains controversial,5,6 
as consensus regarding the clinical definition 
has not yet been reached. Some guidelines 
classify asthma cases with a persistent 
airway obstruction as COPD, and the two 
diseases are often mutually exclusive in 
studies to obtain unblended populations 
of patients with asthma and patients with 
COPD. In addition, the prevalence of a 
concomitant diagnosis of asthma and COPD 
varies greatly in different studies. 
This study aimed to quantify the point 
prevalence of concomitant asthma and 
COPD in the diagnosed populations of both 
patients with asthma and patients with COPD 
in the UK using electronic health record 
databases, where validated definitions exist 
for the identification of both diseases. In 
addition, possible misdiagnosis and missed 
diagnosis in patients with obstructive lung 
diseases were examined.
METHOD
Study population and validation studies
The study populations consisted of people 
who were included in earlier validation 
studies7,8 and are summarised in Figures 1 
and 2. Questionnaires were sent out to the 
GPs of possible patients with asthma and 
patients with COPD with the intent to validate 
the recording of asthma and COPD in the 
Clinical Practice Research Datalink (CPRD). 
The full selection criteria of both validation 
studies can be found in their respective 
articles.7,8 Data collection for the asthma 
validation study was from 1 December 2013 
to 30 November 2015. Data collection for 
the COPD validation study was between 1 
January 2004 and 31 December 2012. In the 
Research
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Patients with validated asthma and patients with 
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the diseases were confirmed by review of GP 
questionnaires. 
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based on CPRD coding, GP questionnaires, and 
requested additional information. 
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(95% confidence interval [CI] = 11.3 to 19.0) of 
patients with validated asthma. More than half 
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had previously received a diagnostic asthma Read 
code. However, when considering additional 
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concurrent asthma was only likely in 14.5% (95% 
CI = 11.2 to 18.3) of patients with validated COPD.
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diagnosis may be over-recorded in people with 
COPD. 
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asthma validation study, full data were only 
available for the patients for whom the GP 
stated a current asthma diagnosis and only 
current asthma diagnoses were considered. 
In the COPD validation study, the population 
was preselected as current or ex-smokers. 
The two patient populations included in 
this study have been thoroughly validated 
in their respective validation studies using 
these detailed GP questionnaires and 
requested supporting information, including 
outpatient referral letters, other emergency 
department discharge letters, airflow 
measurements, and radiography records. In 
the validation studies, the positive predictive 
value was 86.5% (range 77.5–92.3%) for 
COPD8 and 86.4% (range 77.4–95.4%) for 
asthma7 when only using a single diagnostic 
code for the respective disease.
In the asthma questionnaire, details were 
requested on evidence of airway obstruction, 
current symptoms, smoking history, 
respiratory comorbidities, and Quality and 
Outcomes Framework (QOF) indicators 
[QOF is a national financial incentive 
scheme for GPs in the UK encouraging 
regular disease indicator measurement 
and recording]. The COPD questionnaire 
requested information on COPD diagnosis, 
smoking history, symptoms, spirometry, 
confirmation by a respiratory physician, 
and respiratory comorbidities. Additional 
information available from the medical 
record, including spirometry printouts 
and letters from respiratory physician or 
hospitals, was also requested. Data were 
encrypted twice to ensure anonymity. If a 
questionnaire was returned blank or every 
question was answered ‘unknown’, it was 
considered invalid.
Database
The CPRD GOLD is a large anonymised 
UK primary care database that  is 
representative of the UK population 
with regard to age and sex.9 Diagnostic 
accuracy has been demonstrated to be 
high in CPRD GOLD for many conditions,10 
including asthma and COPD. This database 
contains detailed clinical information on 
diagnoses, prescriptions, laboratory 
tests, symptoms, and hospital referrals of 
included individuals in addition to basic 
sociodemographic information recorded by 
the GPs. In the original validation studies, 
lists of medical codes (Read codes) deemed 
as specific for asthma or COPD were used 
to select algorithms to identify patients with 
asthma and patients with COPD; these 
codes have a high validity in their respective 
validation studies. Read codes are part of 
a hierarchical clinical coding system that 
is used in GP practices in the UK; each 
Read code is linked to a specific string of 
text, which refers to a single diagnosis or 
symptom.
Primary outcome and measurements
The primary outcome for this study was the 
proportion of patients with either asthma 
or COPD who had the other disease in the 
validated asthma and COPD populations. The 
presence of a diagnostic asthma Read code 
and positive reversibility tests supported an 
asthma diagnosis in the COPD population. 
The presence of a diagnostic COPD Read 
code, smoking history, and fixed airflow 
obstruction supported a current COPD 
diagnosis in the population with validated 
asthma. Spirometry measurements with 
at least one airflow measurement with 
forced expiratory volume in 1 second 
to forced vital capacity ratio (FEV1/FCV) 
≤70% were considered as evidence for an 
obstructive airflow limitation. The quality of 
the spirometry procedure undertaken in UK 
primary care to diagnose COPD is high, as 
determined in a previous validation study.11
Possible misdiagnosis and/or lacking 
diagnosis of asthma in patients with 
validated COPD, and vice versa, were 
examined using spirometry measurements, 
results of reversibility tests, and smoking 
history. To study the temporality of recorded 
diagnostic Read codes in patients with 
concomitantly recorded asthma and COPD, 
the researchers reported the proportion of 
patients where the time lapse between the 
date of validation of one disease and the last 
known diagnosis of the other disease was 
>2 years. This methodology was adopted 
when the researchers learned, from the 
validation studies, that a patient with COPD 
would sometimes receive their first asthma 
diagnosis in the 2 years leading up to the first 
How this fits in
The prevalence of concomitant asthma 
and COPD is likely to be overestimated in 
studies using only electronic health records 
as their symptoms are similar. This study 
reports on this issue by including only 
patients with validated asthma and patients 
with validated COPD from two previous 
validation studies. It was found that 
concurrent asthma and COPD diagnosis 
affected a relative minority of patients in 
primary care with either asthma (14.8%) 
or COPD (14.5%), suggesting that asthma 
may be over-recorded in people with COPD 
in electronic health records. 
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COPD diagnosis. An asthma code shortly 
before a first diagnosis of COPD is likely to 
be a misdiagnosis of asthma. If the asthma 
code was given multiple years before the 
COPD diagnosis, asthma before COPD onset 
is more probable. 
Conversely, if the last COPD code was 
given >2 years before the validation of an 
asthma diagnosis (and the validated asthma 
diagnosis is assumed to be true), the COPD 
might be misdiagnosed as the code was not 
repeated afterwards.
Asthma and COPD diagnoses are based 
on symptoms, signs, and spirometry, but 
there is no clear reference test. A panel 
consisting of two physicians determined 
whether asthma or COPD were present 
in the validated patients using all available 
information, and according to national and 
international guidelines. Both physicians 
were blind to the patient selection algorithm 
and adjudicated the asthma and COPD 
statuses independently. Where opinion 
differed, the cases were discussed and 
agreement was reached by consensus. 
Statistical analysis
The researchers calculated the proportion 
of patients with asthma with COPD and 
vice versa with 95% confidence intervals 
(CIs) using exact binomial Clopper–Pearson 
intervals. Cells with less than five entries 
were merged for presentation. All analyses 
were conducted using Stata (version 14.0) 
in 2017. 
RESULTS
Background characteristics
The baseline characteristics of the 
751 patients with confirmed asthma and 
COPD diagnoses are shown in Table 1. 
Among patients with validated asthma, those 
with a COPD diagnosis were older than those 
without (67 and 45 years, respectively). There 
was no noticeable difference in mean age 
between patients with validated COPD with 
or without an asthma Read code (73 years in 
both groups). Most of the validated asthma 
study population was female (61%), whereas 
the validated COPD population was more 
evenly split regarding sex (51% male). Table 
1 is further split into two age categories: 
in the patients with validated asthma, a 
concomitant COPD diagnosis is more likely 
when the patient is >50 years of age. Only a 
small percentage of validated patients with 
COPD were ≤50 years of age.
Patients with validated asthma
In total, 351 patients with a validated asthma 
diagnosis were studied, of whom 52 (15%) 
had a recorded COPD Read code. Details 
are summarised in Figure 1. For six of the 52 
patients with asthma and with COPD codes, 
the COPD codes were given >2 years prior 
to asthma validation. For the remaining 
46, COPD codes were within 2 years of 
the asthma validation date. Of the 46 with 
validated asthma and recent COPD codes, 
38 were smokers or ex-smokers and eight 
were recorded as never-smokers. Out of 299 
patients with asthma without COPD codes, 
112 were (ex-)smokers, whereas 187 were 
recorded as never-smokers.
Concomitant asthma and COPD in 
patients with validated asthma was 
assumed in the following scenarios: if the 
patients with validated asthma had a recent 
Table 1. Baseline characteristics of patients with confirmed asthma and COPD diagnoses (N = 751)
 Asthma validation COPD validation
 COPD  No COPD  Asthma No asthma 
Characteristic Read code Read code Total Read code Read code Total
All patients 
 Individuals, n (%) 52 (15) 299 (85) 351 210 (52) 190 (48) 400 
 Mean age, years (95% CI) 67 (64–70) 45 (42–47) 48 (46–50) 73 (71–74) 73 (72–75) 73 (72–74) 
 Sex, male, n (%) 22 (42) 114 (38) 136 (39) 99 (47) 104 (55) 203 (51) 
 (Ex-)smoker,a n (%) 43 (82) 112 (37) 155 (44) – – –
Patients aged ≤50 years 
 Individuals, n (%) 4 (2) 172 (98) 176 9 (75) 3 (15) 12 
 Sex, n male (%) 2 (50) 73 (42) 75 (43) 2 (22) 2 (67) 4 (33) 
 (Ex-)smokera, n (%) 4 (100) 48 (28) 52 (30) – – –
Patients aged >50 years 
 Individuals, n (%) 48 (27) 127 (73) 175 201 (52) 187 (48) 388 
 Sex, male, n (%) 20 (42) 41 (32) 61 (35) 97 (48) 102 (55) 199 (51) 
 (Ex-)smokera, n (%) 39 (81) 64 (50) 103 (59) – – –
aCOPD population was preselected to only include (ex-)smokers. COPD = chronic obstructive pulmonary disease.
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diagnosis of COPD and were smokers or 
(ex-)smokers (n = 38); or if they showed 
obstruction on their spirometry and were 
smokers or (ex-)smokers but lacked a 
COPD code (n = 14). As such, concomitant 
asthma and COPD was likely in 52 patients 
(14.8%, 95% CI = 11.3 to 19.0) 
Solitary asthma (without COPD) was 
assumed in patients with validated asthma 
in three scenarios: either if they did not have 
a COPD code or showed obstruction on 
lung function tests (n = 187 never-smokers 
and n = 98 ex-smoke); if they had a past 
COPD code >2 years ago (as the coding 
should have been repeated) (n = 6); or if they 
had a recent COPD code but no smoking 
history (n = 8). As such, a solitary diagnosis 
of asthma was likely in 299 patients (85.2%, 
95% CI = 81.0 to 88.7). 
Patients with validated COPD
A total of 400 patients with a validated 
COPD diagnosis were studied, of which 210 
(52.5%) had a recorded asthma Read code. 
297 234 people with an asthma
code or symptoms between
1 December 2013 and
30 November 2015
684 questionnairies sent out to
potential patients with asthma
52 asthma patients with
COPD Read codes
475 valid responses
351 validated patients with asthma
124 patients where no asthma
diagnosis was confirmed
190 non-responders,
19 invalid responses
116 patients migrated to other
database systems
Six asthma patients with COPD
Read codes >2 years
before asthma validation
800 questionnairies requested,
100 for each of eight
validation strategies
46 asthma patients with COPD
Read codes within 2 years
of asthma validation
299 asthma patients without
COPD Read codes
Lung function
test result
(Ex)-
smokers, n
Never-
smokers, n
    Obstruction
No obstruction
Total
23
8
8
Total, n
46
15
38
Lung function
test result
(Ex)-
smokers, n
Never-
smokers, n
Obstruction
No obstruction
Total
14 11
176
25
274
187
Total, n
299
98
112
Patients, n  %
10.8
4.0
81.2
4.0
Possible lack of COPD diagnosis
Asthma only correctly diagnosed
COPD presumably misdiagnosed
Confirmed concomitant diagnosis 7.8 to 14.6
2.2 to 6.6
76.7 to 85.1
2.2 to 6.6
95% CI
Concomitant asthma
and COPD
Solitary asthma
285
14
14
38
Figure 1. Selection process of patients with validated 
asthma. COPD = chronic obstructive pulmonary disease.
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Details are summarised in Figure 2. For 82 
of the 210 patients with COPD with asthma 
codes, the asthma codes were >2 years 
prior to COPD validation. For the remaining 
128, asthma codes were within 2 years of 
the COPD validation date. Of the 128 with 
validated COPD and recent asthma codes, 
42 had a recording of positive reversibility 
testing and 86 did not have a recording 
of positive reversibility testing. Out of 190 
patients with COPD without asthma codes, 
16 had a recording of positive reversibility 
testing, whereas 174 did not have lung 
function tests indicating reversibility of their 
airflow obstruction.
Concomitant asthma and COPD were 
assumed in validated patients with COPD 
in two scenarios: validated patients with 
COPD and with a recently recorded asthma 
code and a recording of positive reversibility 
testing (n = 42); and validated patients with 
COPD and without a recent asthma code 
210 COPD patients with
asthma Read codes
128 COPD patients with asthma
Read codes within 2 years
of COPD validation
Patients, n %
8.8
1.8
43.5
20.5
COPD not confirmed
COPD only correctly diagnosed
Asthma prior to COPD
Confirmed concomitant diagnosis 6.2 to 12.0
0.7 to 3.6
4.0Possible lack of asthma diagnosis 2.3 to 6.4
38.6 to 48.5
21.5Asthma presumably misdiagnosed 17.6 to 25.9
16.6 to 24.8
95% CI
951 questionnaires sent out to
potential COPD patients
696 valid responses
400 validated COPD patients
296 patients where no COPD
was diagnosis was confirmed
221 non-responders,
34 invalid responses
82 COPD patients with asthma
Read codes >2 years
before COPD validation
Random sample of 126 patients in
eight algorithms
190 COPD patients without
asthma Read codes
Lung function
test result Reversible, n
Non-
reversible, n
Obstruction
No obstruction
Total
73
86
Total, n
128
7 13
108
20
42
Lung function
test result Reversible, n
Non-
reversible, n
Obstruction
No Obstruction
Total
16
139
35
174
Total, n
19016
803 312 people with COPD code
or symptoms over 35 years
with evidence of smoking
Concomitant asthma
and COPD
Solitary COPD
35
7
16
174
86
82
35
Figure 2. Selection process of patients with validated 
COPD. COPD = chronic obstructive pulmonary disease.
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but with positive reversibility testing recorded 
(n = 16). As such, concomitant asthma and 
COPD was likely in 58 patients (14.5%, 95% 
CI = 11.2 to 18.3).
Solitary COPD (without asthma) was 
assumed in patients with validated COPD 
based on the following criteria: validated 
patients with COPD with no asthma codes 
or recording of positive reversibility testing 
(n = 174); validated patients with COPD where 
the last asthma code was >2 years before 
asthma validation (indicating asthma prior 
to COPD) (n = 82); and validated patients 
with COPD with recent asthma codes but 
without positive reversibility testing (n = 86). 
As such, COPD without clear evidence of 
current asthma was likely in the remaining 
342 patients (85.5%, 95% CI = 81.7 to 88.8).
DISCUSSION
Summary
The researchers investigated the prevalence 
of COPD in patients with validated asthma 
and vice versa using CPRD GOLD data 
on smoking, spirometry, and reversibility 
testing; in addition to detailed GP 
questionnaires and supporting information 
including outpatient referral letters, other 
emergency department discharge letters, 
airflow measurements, and radiography 
records. The main finding of this study was 
that the 14.8% of patients with validated 
asthma had a concurrent COPD diagnosis, 
whereas 14.5% of validated patients with 
COPD had a concurrent asthma diagnosis. 
Asthma may also be over-recorded in CPRD 
GOLD for patients with COPD.
However, more than half of the patients 
with validated COPD had previously received 
an asthma diagnosis Read code, suggesting 
that overdiagnosis of asthma in patients with 
COPD commonly occurs, particularly early 
in the diagnostic process. Overdiagnosis of 
COPD in patients with asthma is less likely.
Strengths and limitations
This study has potential limitations that need 
consideration. First, the results of this study 
are only applicable to the records in the 
CPRD, although this database is considered 
representative of the general UK population.9 
Second, only patients with asthma and 
patients with COPD for whom their GP 
responded to verify their diagnosis in the 
original questionnaire were included in this 
study. GPs of more complicated cases might 
be less likely to respond where diagnostic 
uncertainty may exist. However, this issue is 
mitigated to an extent as GPs were paid for 
providing the information for validation, and 
the baseline characteristics of the individuals 
for whom a questionnaire was returned were 
similar to the characteristics for which no 
questionnaire was returned.8 Data on eligible 
patients who were not included, as there was 
no returned questionnaire, were available 
from CPRD GOLD, but did not contain all the 
information of a completed questionnaire. 
Third, the validation process was mostly 
based on the GP questionnaires, which are 
available in the original studies.8 Additional 
information (discharge letters, spirometry 
measurements, and radiography) were 
available for 31.5% of patients with asthma. 
This means the strength of evidence for 
confirmation or rejection of recorded 
diagnosis in CPRD varied among the 
participants, and a panel diagnosis for chronic 
respiratory diseases can be considered as 
subjective. In the original validation studies, 
positive predictive values were calculated 
separately for people for whom additional 
information was and was not provided, with 
similar results in these sensitivity analyses. 
Fourth, the researchers assumed the 
samples were representative of the asthma 
and COPD populations, whereas both 
sampling methods were based on possible 
identification strategies. The identification 
strategies or algorithms used for sampling 
are described in detail in their respective 
validation studies.8,12 
Fifth, this study clarifies the burden of 
concomitant asthma and COPD diagnosis in 
primary care, but additional information on 
how these patients are treated is needed in 
further studies. 
Sixth, the COPD population was selected 
to include only current or ex-smokers. This 
implies that this study’s findings in the COPD 
populations are only valid for (ex-)smokers. 
Finally, GPs could have more information 
on the clinical status, which was not shared 
in the questionnaire. This risk is present but 
diminished as the provision of additional 
information was remunerated.
This study has a few strengths. First, it was 
possible to quantify the burden of concomitant 
diagnosis of asthma and COPD in a large 
cohort of primary care patients (CPRD 
GOLD), which is representative in terms of 
age and sex to the general UK population. 
Second, information included in both the 
CPRD GOLD and in the questionnaires 
sent out for the original validation studies 
was used in order to differentiate between 
asthma and COPD. Finally, this study adds to 
the relatively small body of literature on the 
epidemiology of concomitant asthma and 
COPD in primary care.
Comparison with existing literature
In primary care, most consultations on 
respiratory diseases start with a provisional 
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diagnosis made on clinical grounds from 
the patients’ symptoms, in addition to 
previous specialists’ correspondence 
if available.13–16 Spirometry is needed to 
accurately differentiate the diagnosis of 
asthma and COPD, but is not always used 
in a primary care setting.17–20
The prevalence of asthma in COPD 
populations is lower compared with many 
previously published studies, especially 
those based on electronic health records. 
However, the prevalence of COPD in asthma 
populations is similar to a previous cross-
sectional study measuring the prevalence 
for comorbidities in asthma, which reported 
that 13.4% of patients with asthma had a 
COPD diagnosis compared with 3.4% of the 
remaining general population.21 A previous 
systematic review stated a pooled prevalence 
of asthma in patients with COPD of 27%, with 
considerable heterogeneity12 The definition 
of asthma and COPD diagnosis tends to 
differ between studies, which might explain 
this observation. A study using Norwegian 
GP data confirmed COPD diagnosis using 
spirometry in 17.1% of patients with only a 
previous asthma diagnosis.22 Among subjects 
with a spirometry-based study diagnosis 
of COPD in GP practices in Scotland and 
the US, 51.5% reported a prior diagnosis 
of asthma without a concurrent chronic 
bronchitis or emphysema diagnosis.23 A 
systematic review on ACOS in 2015 found 
a pooled prevalence of 27% in population-
based studies of patients with COPD and 
28% in hospital-based studies of patients 
with COPD.12 A recent multicentre study on 
patients with COPD in Japan found an asthma 
prevalence of 9.2% or 4.2%, depending on 
the FEV1 cut-off.24 Other studies report a 
very wide range of prevalence of concomitant 
asthma and COPD as the diagnosis criteria 
are heterogeneous and a consensus on 
diagnostic criteria is needed.4,5 
Implications for research and practice 
This study suggests that overdiagnosis of 
asthma in patients with COPD is more likely 
than overdiagnosis of COPD in patients 
with asthma. COPD is possibly more 
conservatively diagnosed as it is considered 
a more severe disease, whereas asthma 
can be more liberally diagnosed. In addition, 
a patient with COPD can be diagnosed 
with asthma in the years before first COPD 
diagnosis, after which no further recording of 
asthma is made, suggesting that the asthma 
diagnosis was likely to be false. In patients 
with presumed concomitant diagnosis of 
asthma and COPD, reversibility testing can 
be used to verify the asthma diagnosis. 
The findings from the present study 
have implications for further research into 
concomitant asthma and COPD. Identifying 
potential concomitant asthma and COPD 
using electronic health records should be 
done cautiously. If only a single code for both 
diseases is required for the identification 
algorithm, the prevalence of concomitant 
diagnosis of asthma and COPD is likely to be 
overestimated. 
In addition, this study also has implications 
for the management of patients with COPD 
with a past asthma diagnosis, as the previous 
asthma diagnosis might be either outdated 
or misdiagnosed. Incorrect management can 
expose patients to adverse effects and incur 
additional costs for them and the health 
system; for example, through unnecessary 
medication regimens such as the usage of 
montelukast in patients with COPD. This 
study did not go into detail on the current 
treatment of either patients with validated 
asthma or patients with validated COPD. 
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